Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
about
The chemopotentiation of cisplatin by the novel bioreductive drug AQ4NA novel deep red/low infrared fluorescent flow cytometric probe, DRAQ5NO, for the discrimination of intact nucleated cells in apoptotic cell populations.Targeting hypoxic tumour cells to overcome metastasis.Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.Prospects for bioreductive drug development.Enhanced expression of cytochrome P450 in stomach cancer.Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantroneCytochrome P450 CYP3A in human renal cell cancer.Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental dataGene therapy approaches to enhance bioreductive drug treatment.Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies.Design and synthesis of novel hydroxyanthraquinone nitrogen mustard derivatives as potential anticancer agents via a bioisostere approachRadiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities.Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells.Cytotoxicity of anthraquinones from the roots of Pentas schimperi towards multi-factorial drug-resistant cancer cells.Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivoEvidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.Hypoxia-regulated gene network in drug resistance and cancer progression.
P2860
Q28346061-9E3926FD-50DA-4F09-9E4E-633BF3EB030EQ30841008-A42E3B68-4EA5-43FB-BB46-FF71D43BB609Q34086671-B8FBED8C-A815-4DF4-8FC6-C738172ABE37Q34819107-A91C315F-2276-4814-ACCF-0D7C2A5687BFQ35087333-028732CE-72AD-4C01-9924-BE2BD07D1E6EQ36135032-D2272AF4-15C7-425E-BEF4-C70480824CCBQ36181210-CFA324C7-703F-4AA0-A6CC-7E58F361F794Q36292285-950C31BB-A905-4528-8509-B1A0924CB7A9Q36573248-782CA412-83C3-4F27-BA6A-45A05FCAC19FQ36619261-4E4A2E7C-86BF-43BE-8856-F2A3D8CAFC43Q36620877-E359B58F-EC40-4D9A-A130-AEFCDDBA2176Q36621020-2009CEA4-F257-44BA-898B-C773351E4DEBQ36621361-0024ECB3-BAE6-48A5-9272-AA580B8E715CQ36795109-C973E0F4-48DF-4897-8861-98D2BCDF2276Q37280249-ACBC1BFC-DC44-4187-BB66-01DD5249C74BQ37872235-2AF49C72-6334-4AA3-AF6A-99AC800A6BAFQ38309433-8B8FC528-DD72-42C4-ADF6-5016A77FD3CFQ38722296-51B44074-1D9A-40A1-A6F6-E782D4ECEB4FQ38778147-5873A937-8535-4737-9A94-00764F75D951Q38838150-E2C69C00-6973-41A8-BA65-B779D6B13C12Q38859679-DDBFF9DE-03EB-4D14-9992-AEE2B77E8032Q40330281-3D737E54-371E-4495-A196-8042FD72919AQ41771687-56447079-C6D6-4D05-A03B-21EDE70EF72EQ41844441-604EB87A-F990-4A97-A272-28846D266A23Q41961353-C3A742AB-1F96-4236-AE3D-881D348D8B19Q51693639-27628237-A0F4-4E09-8968-D27CD6526D86Q54354000-AEBE3A8B-4036-4D70-BF2B-94A62C41D5DE
P2860
Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Rationale for the use of aliph ...... w class of bioreductive agent.
@en
type
label
Rationale for the use of aliph ...... w class of bioreductive agent.
@en
prefLabel
Rationale for the use of aliph ...... w class of bioreductive agent.
@en
P356
P1476
Rationale for the use of aliph ...... w class of bioreductive agent.
@en
P2093
L H Patterson
P2888
P304
P356
10.1007/BF00689805
P577
1993-06-01T00:00:00Z
P6179
1027992179